Clinical value of circulating splicing factors in prostate cancer: SRRM1 as a novel predictive biomarker and therapeutic target.

Mol Ther Oncol · 2024 · PMC11697196 · PMID 39758250

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The treatment with SRRM1 siRNA tended to reduce the number of mitosis and Ki67 index, although the differences did not reach statistical significance ( Figures 4 D and 4E).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.